Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Risk reduction in drug discovery and development.

Martin Mackay1, Stephen D A Street, John M McCall

  • 1Pfizer Inc., Global Res HQ, 50 Pequot Ave., New London, Connecticut 06320, USA.

Current Topics in Medicinal Chemistry
|September 27, 2005
PubMed
Summary

Aggressively managing risk in pharmaceutical R&D is crucial due to rising costs. Early, data-driven decisions and a reward system valuing negative outcomes improve drug development success.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4- to <7-year children.

Steroids·2025
Same author

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.

Neurology·2019
Same author

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Pharmacological research·2018
Same author

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.

Steroids·2018
Same author

VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.

Inflammation research : official journal of the European Histamine Research Society ... [et al.]·2016
Same author

VBP15, a novel anti-inflammatory, is effective at reducing the severity of murine experimental autoimmune encephalomyelitis.

Cellular and molecular neurobiology·2014

Area of Science:

  • Pharmaceutical R&D
  • Drug Discovery and Development
  • Risk Management

Background:

  • The escalating costs of discovering and developing new pharmaceutical agents necessitate proactive risk management strategies.
  • Current pharmaceutical development processes require earlier, data-informed decision-making to mitigate financial and scientific risks.

Purpose of the Study:

  • To emphasize the critical need for aggressive risk management throughout the pharmaceutical R&D lifecycle.
  • To advocate for integrating risk assessment into technical, strategic, and organizational levels of drug development.

Main Methods:

  • Analysis of decision-making processes in pharmaceutical R&D.
  • Evaluation of the impact of risk management on project outcomes.
  • Review of reward systems in relation to project termination decisions.

Related Experiment Videos

Main Results:

  • Data-driven decisions and experience are key to effective risk management.
  • Addressing uncontrolled risks early improves the likelihood of success in clinical trials, regulatory approval, and market viability.
  • Organizational and strategic alignment is essential for comprehensive risk mitigation.

Conclusions:

  • Effective risk management, starting from discovery and early development, is imperative for pharmaceutical innovation.
  • A cultural shift is needed to view negative decisions as valuable learning opportunities.
  • Proactive and integrated risk management enhances the overall success rate of pharmaceutical agents.